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Abstract: Endothelial nitric oxide synthase (NOS3) is one of the enzymes influencing nitric oxide (NO) function in the 
human brain. NO is a gaseous neurotransmitter that is involved in a variety of mechanisms in the central nervous system, 
such as N-methyl-D-aspartate receptor activation and oxidative stress. The evidence from animal pharmacological studies 
and postmortem studies supports an association between NO and psychotic disorders. Methamphetamine (METH) use 
disorder is a known psychotic disorder, and we therefore conducted a gene-based case-control study between tagging  
single nucleotide polymorphisms (SNPs) (rs2070744, rs1799983) in NOS3 and METH-induced psychosis in Japanese 
subjects (183 with METH-induced psychosis and 267 controls). Written informed consent was obtained from each   
subject. No significant association was found between any tagging SNP in NOS3 and METH-induced psychosis in the  
allele/genotype-wise or haplotype-wise analyses. In conclusion, we suggest that NOS3 might not contribute to the risk of 
METH-induced psychosis in the Japanese population. 
Keywords: Methamphetamine-induced psychosis, endothelial nitric oxide synthase (NOS3), gene-based case-control associa-
tion study. 
1. INTRODUCTION 
  Methamphetamine (METH) is an illegal drug used 
widely in the world, known to cause psychiatric disorder. 
METH releases dopamine in the central nervous system 
(CNS) [1]. Moreover, excess dopamine in the CNS is 
thought to cause psychotic symptoms such as hallucinations 
and delusions [2]. The symptomatologic character of METH-
induced psychosis is similar to that of schizophrenia. A re-
cent study reported METH may cause selective increase of 
Nitric oxide (NO) in the striatum, leading to dopaminergic 
neurotoxicity [3]. 
  NO is a gaseous neurotransmitter involved in a variety of 
mechanisms in the CNS and the vascular system. This mo-
lecular signaling has a role in regulating other neurotransmit-
ters, such as dopamine and serotonin that is involved in neu-
ronal dysfunction in schizophrenia and mood disorder [4, 5]. 
Pharmacological studies in animal models reported an asso-
ciation between NO and behavioral abnormality caused by 
phencyclidine [6-8]. 
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  NO is synthesized from L-arginine by nitric oxide syn-
thase. One of the enzymes influencing NO function in the 
human brain is endothelial nitric oxide synthase (NOS3). 
NOS3 is located on chromosome 7q35-36, including 21 exons 
and spanning 24.33kb. Two functional SNPs (rs2070744, 
rs1799983) in NOS3 have been reported and genetic associa-
tion studies on them have been performed [9, 10]. Much at-
tention has been focused on associations between these func-
tional SNPs in NOS3 and cardiovascular disease. It may be 
that NOS3 controls brain blood flow, producing NO to regulate 
vascular tone. Additionally, NOS3 knockout mouse showed a 
low rate of neural stem cell proliferation, and responsiveness 
in the learned helplessness paradigm, a promising animal 
model of depression [11]. However, there are few genetic 
association studies between NOS3 and psychotic disorders 
[12]. Based on this evidence, we suspected that NOS3 might 
be related to the pathophysiology of METH-induced psycho-
sis, and conducted a genetic association analysis of six tag-
ging SNPs, including two functional SNPs, in NOS3 and 
METH-induced psychosis in the Japanese population. 
2. MATERIALS AND METHODS 
2.1. Subjects 
  The subjects in the association analysis were 183 patients 
(all patients were diagnosed as having METH-induced psy-152    Current Neuropharmacology, 2011, Vol. 9, No. 1  Okochi et al. 
chosis; 151 males and 32 females: mean age ± SD 36.7±11.6 
years) and 267 healthy controls (217 males and 50 females: 
mean age ± SD 35.5 ±14.4 years). There was no significant 
association between the age of the healthy controls and that 
of the patients (Table 1). All subjects were unrelated to each 
other, ethnically Japanese, and lived in Japan. Among the 
subjects with METH use disorder, all subjects had a comor-
bid diagnosis of METH-induced psychosis. One hundred 
forty-nine subjects with METH use disorder abused or had 
dependence on drugs other than METH. Cannabinoids were 
the most frequently abused drugs (31.4%), followed by co-
caine (9.09%), LSD (9.09%), opioids (7.69%), and hypnotics 
(7.69%). Subjects with METH use disorder were excluded if 
they had a clinical diagnosis of psychotic disorder, mood 
disorder, anxiety disorder, or eating disorder. The patients 
were diagnosed according to DSM-IV or ICD-10 criteria 
with consensus of at least two experienced psychiatrists on 
the basis of unstructured interviews and a review of medical 
records. All healthy controls were also psychiatrically 
screened through unstructured interviews, and those with 
past individual or family history of drug dependence or axis 
1 disorders such as psychotic or mood disorders were ex-
cluded. After describing the study, written informed consent 
was obtained from each subject. This study was approved by 
the Ethics Committee at Fujita Health University and each 
participating institute of the Japanese Genetics Initiative for 
Drug Abuse (JGIDA). 
2.2. SNP Selection and Genotyping 
  We first consulted the HapMap database (release#21a, 
Jan 2007 www.hapmap.org, population: Japanese Tokyo: 
minor allele frequencies (MAFs) of more than 0.05) and 
found 32 SNPs covering NOS3. Then 5 ‘tagging SNPs’ were 
selected with the criterion of an r2 threshold greater than 0.8 
in ‘pair-wise tagging only’ mode using the ‘Tagger’ program 
(Paul de Bakker, http://www/broad.mit.edu/mpg/tagger), using 
the HAPLOVIEW software. We selected 6 SNPs that included 
functional polymorphisms (rs1800779, rs2070744, rs1799983, 
rs3918188, rs743507, rs7830) in NOS3. 
  We used TaqMan genotyping assays (Applied Biosys-
tems) for all SNPs.  
2.3. Statistical Analysis 
  Genotype deviation from the Hardy-Weinberg equilib-
rium (HWE) was evaluated with the chi-square test 
(SAS/Genetics, release 8.2, SAS Japan INC, Tokyo, Japan). 
Marker-trait association was also evaluated with the chi-
square test in allele- and genotype-wise analyses. Haplotype 
frequencies were estimated in a two- to four-marker sliding 
window fashion and log likelihood ratio tests were per-
formed for global P-values with COCAPHASE program 
version 3.0.6 [13]. In these haplotype-wise analyses, rare 
haplotypes (less than 0.05) of either cases or controls were 
excluded from the association analysis. Power calculation 
was performed using a statistical program prepared by the 
Genetic Power Calculator (http://pngu.mgh.harv-ard.edu/~ 
purecell//gpc/) [14]. The level of significance for all statistical 
tests was 0.05. 
3. RESULTS 
  Genotype frequencies of subjects and controls did not 
deviate significantly from HWE. No significant association 
was found between NOS3 and METH-induced psychosis in 
the allele/genotype-wise analysis (Table 2) or in the haplo-
type analysis (Table 3). 
  In a power analysis, we obtained more than 80% power 
for the detection of association when we set the genotype 
relative risk at 1.81-2.31, under a multiplicative model of 
inheritance. 
4. DISCUSSION 
  In this study, we performed a genetic association study 
based on LD between NOS3 and METH-induced psychosis. 
However, no association was found between NOS3 and 
METH-induced psychosis in these Japanese subjects in al-
lele/genotype-wise and haplotype-wise analysis. 
  In a recent study using knockout mice, Reif et al. looked 
for an association between NOS3 and mood disorders. They 
suggested that a haplotype including two functional SNPs 
(rs2070744, rs1799983) in NOS3 may influence the suscep-
tibility of bipolar disorder [12]. Additionally, Kawohl et al. 
found an association between rs1799983 and lower respon-
siveness in the loudness dependence of auditory evoked po-
tentials (LDAEP), which is a functional marker of serotoner-
gic transmission [15]. Several pieces of evidence have sug-
gested NOS3 has an important role in the serotonin system in 
the human brain. Therefore, it will be necessary to replicate 
these associations with the same phenotype and others using 
more samples. 
  A few points of caution must be mentioned with regard 
to our findings. (3) It is important to evaluate associations 
between METH use disorder with and without psychosis. 
However, only a small number of subjects had no psychosis, 
and so we did not evaluate this association in order to avoid 
type I error from a small sample size. The small sample size 
was due to the limitations of sample collection, since we 
used cases of METH use disorder in psychiatric hospitals. 
Table 1.  Characteristics of METH-Induce Psychosis and CON Subjects 
 METH-Induced  Psychosis  CON  P-value 
N 183 267   
male 151  217   
female 32  50 0.737 
Age means ± SD  36.704 ± 11.6  35.527 ± 14.44  0.309 Genetic Association Analysis of NOS3 and Methamphetamine-Induced Psychosis  Current Neuropharmacology, 2011, Vol. 9, No. 1    153 
(13*-) We did not include a mutation scan for rare variants. 
Because rare variants with functional effects in NOS3 have 
the possibility of influencing susceptibility of METH-
induced psychosis, further investigations including mutation 
scan using large samples will be required. 
  In conclusion, our results suggest that NOS3 does   
not play a major role in METH-induced psychosis in   
the Japanese population. However, the number of METH 
patients used in this study was small. It will be necessary  
to validate or replicate our association in other, larger   
population samples. 
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Table 2.  Association Analysis between NOS3 and METH-Induced Psychosis 
Genotype Distribution
c  P- Value 
SNP ID  Phenotype
a MAF
b N 
M/M M/m m/m  HWE
d Genotype  Allele 
rs1800779 METH-induced  psychosis  0.117  183  140  43  0  0.0717  0.139  0.248 
  CON  0.0936  267  219  46  2  0.805   
rs2070744 METH-induced  psychosis  0.120  183  140  42  1  0.250  0.357  0.168 
  CON  0.0918  267  219  47  1  0.359   
rs1799983 METH-induced  psychosis  0.0847  183  152  31  0  0.210  0.500  0.787 
  CON  0.0899  267  221  44  2  0.906   
rs3918188 METH-induced  psychosis  0.246  183  107  62  14  0.242  0.286  0.424 
  CON  0.270  267  140  110  17  0.452   
rs743507 METH-induced  psychosis  0.156  183  130  49  4  0.805  0.848  0.609 
  CON  0.169  267  183  78  6  0.489   
rs7830 METH-induced  psychosis  0.484  183  49  91  43  0.952  0.496  0.399 
  CON  0.455  267 85 121 61 0.158     
a  METH:methamphetamine  CON:control 
b MAF: minor allele frequency 
c M: major allele, m: minor allele 
d Hardy-Weinberg equilibrium 
 
Table 3.  Results of Haplotype Analysis between NOS3 and METH-Induced Psychosis 
Global P-value 
SNP ID  2 SNP  3 SNP  4 SNP 
rs1800779      
 0.465     
rs2070744   0.659   
 0.656   0.653 
rs1799983   0.723   
 0.548   0.733 
rs3918188   0.649   
 0.408   0.515 
rs743507   0.410   
 0.622     
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